Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07645495
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef UniversityNot Yet RecruitingNot Applicable
NCT07645495Not Yet Recruiting
Not Applicable
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef University
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07645053
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal SurgeryHospital Edmundo VasconcelosCompletedPhase 1
NCT07645053Completed
Phase 1
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal...Hospital Edmundo Vasconce...
NCT07644026
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet Recruiting
NCT07644026Not Yet Recruiting
—
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology &...
NCT07646054
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers23andMe, Inc.Not Yet RecruitingNot Applicable
NCT07646054Not Yet Recruiting
Not Applicable
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers23andMe, Inc.
NCT07645950
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Montpellier - Val d'AurelleNot Yet Recruiting
NCT07645950Not Yet Recruiting
—
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Mon...
NCT07644221
Feasibility and Effects of Noninvasive Brain Stimulation on Pain Perception in People With FibromyalgiaDepartment of Anesthesiology & Perioperative Medicine, University of PittsburghNot Yet RecruitingNot Applicable
NCT07644221Not Yet Recruiting
Not Applicable
Feasibility and Effects of Noninvasive Brain Stimulation on Pain Perception in P...Department of Anesthesiol...
NCT07644481
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07644481Not Yet Recruiting
Not Applicable
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melpha...Institute of Hematology &...
NCT07645521
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation Following Functional Endoscopic Sinus SurgeryMansoura UniversityCompletedNot Applicable
NCT07645521Completed
Not Applicable
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation...Mansoura University
NCT07644013
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First HospitalRecruiting
NCT07644013Recruiting
—
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First H...
NCT07645469
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaFred Hutchinson Cancer CenterNot Yet RecruitingPhase 1
NCT07645469Not Yet Recruiting
Phase 1
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Di...Fred Hutchinson Cancer Ce...
NCT07646171
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)Tel-Aviv Sourasky Medical CenterRecruiting
NCT07646171Recruiting
—
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+)...Tel-Aviv Sourasky Medical...
NCT07644416
Using Virtual Reality Travel to Reduce Loneliness in Older AdultsIndiana UniversityNot Yet RecruitingNot Applicable
NCT07644416Not Yet Recruiting
Not Applicable
Using Virtual Reality Travel to Reduce Loneliness in Older AdultsIndiana University
NCT07644923
Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated CoagulationNYU Langone HealthNot Yet RecruitingPhase 4
NCT07644923Not Yet Recruiting
Phase 4
Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled Wit...NYU Langone Health
NCT07644312
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPGNationwide Children's HospitalNot Yet RecruitingPhase 2
NCT07644312Not Yet Recruiting
Phase 2
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG...Nationwide Children's Hos...
NCT07645248
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)GlaxoSmithKlineNot Yet RecruitingPhase 3
NCT07645248Not Yet Recruiting
Phase 3
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1...GlaxoSmithKline
NCT07645014
Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Polycystic Ovarian Syndrome.Riphah International UniversityRecruitingNot Applicable
NCT07645014Recruiting
Not Applicable
Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Polyc...Riphah International Univ...
NCT07645820
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis FlaresCastle Biosciences IncorporatedRecruiting
NCT07645820Recruiting
—
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Fla...Castle Biosciences Incorp...
Result Breakdown
Not yet recruiting14 (70%)
Recruiting4 (20%)
Completed2 (10%)
not_applicable7 (35%)
Not Specified7 (35%)
Phase 13 (15%)
Phase 41 (5%)
Phase 21 (5%)
Phase 31 (5%)